MiMedx Group, Inc. (MDXG)
| Market Cap | 484.47M -56.0% |
| Revenue (ttm) | 303.73M -22.8% |
| Net Income | -19.19M |
| EPS | -0.13 |
| Shares Out | 145.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,225,252 |
| Open | 3.340 |
| Previous Close | 3.370 |
| Day's Range | 3.280 - 3.420 |
| 52-Week Range | 3.025 - 7.660 |
| Beta | 1.18 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+110.84%) |
| Earnings Date | Oct 28, 2026 |
About MDXG
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The co... [Read more]
Financial Performance
In 2025, MiMedx Group's revenue was $418.63 million, an increase of 19.99% compared to the previous year's $348.88 million. Earnings were $48.58 million, an increase of 14.52%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for MDXG stock is "Strong Buy." The 12-month stock price target is $7.0, which is an increase of 110.84% from the latest price.
News
MiMedx Group Transcript: Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum
Q3 delivered positive adjusted EBITDA and free cash flow, while surgical sales grew 9% YoY. The pending Sanara deal targets roughly $400M in revenue and adjusted EBITDA margins above 20% in its first year.
MIMEDX to Participate in Upcoming Investor Conferences
MARIETTA, Ga., Nov. 06, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following i...
MiMedx price target lowered to $7 from $8 at Craig-Hallum
Craig-Hallum analyst Chase Knickerbocker lowered the firm’s price target on MiMedx (MDXG) to $7 from $8 and keeps a Buy rating on the shares. The firm notes the company reported…
MiMedx price target lowered to $7 from $8 at Mizuho
Mizuho analyst Anthony Petrone lowered the firm’s price target on MiMedx (MDXG) to $7 from $8 and keeps an Outperform rating on the shares.
MiMedx enters $25M patent license agreement with wound care competitor
MiMedx (MDXG) announced that it has entered into a license agreement with a wound care competitor that resolves allegations of infringement of MiMedx’s patents. The licensee will pay MiMedx a…
MiMedx Group Earnings Call Transcript: Q3 2026
Q3 sales fell 45% YoY as Medicare-related wound pressure persisted, while surgical volume grew at a mid-teens rate. Cost reductions returned Adjusted EBITDA to positive territory; Sanara's closing is delayed by an FTC second request.
MiMedx Group Quarterly report: Q3 2026
MiMedx Group has published its Q3 2026 quarterly earnings report on October 28, 2026.
MiMedx Group Earnings release: Q3 2026
MiMedx Group released its Q3 2026 earnings on October 28, 2026, summarizing the period's financial results.
MiMedx reports Q3 adjusted EPS (1c), consensus 0c
Reports Q3 revenue $62.28M, consensus $68.72M. Joseph Capper, MiMedx (MDXG) Chief Executive Officer, commented, “Our third quarter results reflect the progress we have made in reshaping MIMEDX into a ...
MiMedx cuts FY26 revenue view to $250M-$260M from $260M-$290M
Consensus $267.02M. The company said, “For 2026, MIMEDX (MDXG) now expects 2026 net sales to be in a range of $250 to $260 million. The Company expects Adjusted EBITDA for…
MIMEDX Announces Third Quarter 2026 Operating & Financial Results
Reports Continued Double-Digit Year-Over-Year Volume Growth for Surgical Franchise Delivers Wound Care Center Volume Growth Both Sequentially and Year-Over-Year Obtained Favorable Federal Court Ruling...
MIMEDX Announces $25 Million Patent License Agreement
MARIETTA, Ga., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into a license agreement with a wound care competitor...
MiMedx Group Slides: Investor presentation
MiMedx Group has posted slides in relation to its latest quarterly earnings report, which was published on October 28, 2026.
MiMedx, Sanara received requests for additional information from FTC
In a regulatory filing, MiMedx (MDXG) noted that, as previously announced, MiMedx Group entered into an agreement and plan of merger with Sanara MedTech (SMTI), pursuant to which, among other…
MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026
MARIETTA, Ga., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third qua...
MiMedx announces ‘favorable’ federal court ruling on Axiofill
MiMedx (MDXG) Group announced that the U.S. District Court for the Northern District of Georgia issued a favorable ruling in the company’s litigation challenging the FDA regulatory classification of A...
MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter
Court Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified as a Biological Product
MiMedx price target raised to $8 from $6 at Craig-Hallum
Craig-Hallum raised the firm’s price target on MiMedx (MDXG) to $8 from $6 and keeps a Buy rating on the shares. The pending acquisition of Sanara MedTech (SMTI) gives the…
MiMedx price target raised to $7 from $5 at Lake Street
Lake Street analyst Brooks O’Neil raised the firm’s price target on MiMedx (MDXG) to $7 from $5 and keeps a Buy rating on the shares after the company agreed to…
MiMedx to acquire Sanara MedTech for $35 per share, $350M enterprise value
MiMedx Group (MDXG) and Sanara MedTech (SMTI) announced that they have entered into a definitive merger agreement under which MiMedx will acquire all of the outstanding shares of Sanara in…
MiMedx reports Q2 EPS (5c), consensus (3c)
Reports Q2 revenue $64.36M, consensus $63.46M. Joseph H. Capper, MiMedx (MDXG) Chief Executive Officer, commented, “During the second quarter, we delivered another strong performance in our Surgical f...
MiMedx Group Earnings Call Transcript: Q2 2026
Announced acquisition of Sanara MedTech, creating a leading regenerative medicine company with a strong surgical focus. Q2 2026 saw sequential recovery in wound care and 15% year-over-year growth in surgical, with net sales of $64 million. Combined company expects over $400 million revenue and 20%+ adjusted EBITDA margin in 2027.
MiMedx Group Quarterly report: Q2 2026
MiMedx Group has published its Q2 2026 quarterly earnings report on July 29, 2026.
MiMedx Group Earnings release: Q2 2026
MiMedx Group released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
MiMedx Group Press release: Q2 2026
MiMedx Group issued a press release on July 29, 2026, disclosing material business information to investors.